On that basis Astex/Otsuka has validated the investment opportunity. They are partnering with us to support the Phase 1/2 Investigator AML trial. They would not have done this unless they were satisfied with the data around bisantrene.
More importantly the investigator who approached us would not have come to us wanting to run an AML trial unless they thought bisantrene was something special. They can put each of their patients into a couple of dozen different AML trials and been paid handsomely by the pharmaceutical companies to do so. The fact they came to us to get access to RC220 is more of an endorsement than any minor investment from a large pharma that gives away all the upside would ever be.
Ann: Updated Strategy and Investor Presentation, page-44
-
- There are more pages in this discussion • 465 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |